Skip to main content
Fig. 4 | Acta Neuropathologica Communications

Fig. 4

From: IDH-wild type glioblastomas featuring at least 30% giant cells are characterized by frequent RB1 and NF1 alterations and hypermutation

Fig. 4

Impact of EGFR amplification and hypermutation on clinical outcome. The overall survival of patients with glioblastomas enriched in giant cells and harboring EGFR amplification (P = 0.004), or TMB < 10 mutations/Mb (P = 0.0263) was significantly shorter than that of patients with giant cells enriched glioblastoma lacking EGFR amplification or having TMB ≥ 10 mutations/Mb

Back to article page

Acta Neuropathologica Communications

ISSN: 2051-5960

Contact us